Communicable Diseases  >>  samatasvir (IDX719)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
samatasvir (IDX719) / Merck (MSD)
NCT01852604: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Checkmark EASL 2014: HELIX-1
Mar 2014 - Mar 2014: EASL 2014: HELIX-1
Checkmark EASL 2014: HELIX-1
Mar 2014 - Mar 2014: EASL 2014: HELIX-1
Checkmark HELIX-1 trial for hep C infection
More
Completed
2
143
US
Samatasvir, Simeprevir, Ribavirin (RBV), TMC647055, Ritonavir (RTV), Pegylated interferon (Peg-IFN), Samatasvir matching placebo
Merck Sharp & Dohme LLC, Janssen Research & Development, LLC
Chronic Hepatitis C Virus
04/15
04/15
NCT01508156: Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)

Checkmark EASL 2013
Apr 2013 - Apr 2013: EASL 2013
Completed
1/2
130
US
IDX719, Placebo
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
07/12
07/12

Download Options